Atezolizumab Significantly Improves OS in Locally Advanced or Metastatic NSCLC

In contrast with docetaxel, atezolizumab improved overall survival among patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after platinum-based chemotherapy, according to preliminary results from the phase 3 OAK trial.¹

For international, open-label, OAK study, investigators randomly assigned 1225 patients to receive either atezolizumab or docetaxel every 3 weeks until disease progression or unacceptable toxicity.

Full results will be submitted for presentation at an upcoming medical meeting in 2016.

A Biologics License Application for atezolizumab in NSCLC was granted Priority Review and action by the U.S. Food and Drug Administration (FDA) is expected by October 19, 2016.

Atezolizumab is already approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.                             

Reference

1. Phase III study showed Genentech’s cancer immunotherapy Tecentriq (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy [press release]. Genentech website. http://www.gene.com/media/press-releases/14634/2016-08-31/phase-iii-study-showed-genentechs-cancer. Updated August 31, 2016. Accessed September 1, 2016.